SFDA Issues Recall System For Medical Devices
This article was originally published in PharmAsia News
Executive Summary
China's State FDA released a draft on administrative measures for medical device recalls on March 19. The report specifies the responsibility, recall scope, time limit, classification and legal liabilities of medical device recalls, mainly aimed at device manufacturers. Recall falls into two types: voluntary and compulsory. Based on the potential safety hazard of medical devices, three categories of recall have been classified: devices that must be recalled within 24 hours, 48 hours and 72 hours. Industry analysts observe that as most local medical devices makers are small-scale enterprise, they may not be able to bear losses. However, the new recall system will have a profound impact on enhancing manufacturers' quality control and focus on their medical devices. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.